View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 20, 2020updated 21 May 2020 5:10am

Bharat Biotech and Thomas Jefferson partner on Covid-19 vaccine

India-based Bharat Biotech has entered into an exclusive agreement to develop a new Covid-19 vaccine candidate created at Thomas Jefferson University in Philadelphia, US.

India-based Bharat Biotech has entered into an exclusive agreement to develop a Covid-19 vaccine candidate created at Thomas Jefferson University in Philadelphia, US.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Infectious Diseases expert professor Matthias Schnell’s lab created the vaccine candidate in January using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.

This approach, used as a vehicle or carrier vaccine, is known to generate a strong immune response, authorised for the whole population, including children and pregnant women.

In preliminary tests in animal models, the vaccine demonstrated a strong antibody response in mice. Currently, the researchers are evaluating if vaccinated animals are protected from Covid-19 infection and results are expected to be available next month.

Schnell noted: “Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development. We will be able to complete animal testing and move to Phase I clinical trial rapidly.”

As part of the licence agreement, the company gets exclusive rights to develop, market and deliver Jefferson’s vaccine globally, excluding some countries such as the US, Europe and Japan, where Jefferson is seeking partners.

With the Indian government’s Department of Biotechnology support, the company intends to advance the vaccine candidate into human trials as early as December this year.

Bharat Biotech CEO Dr Krishna Mohan said: “In view of the imminent demand for an effective vaccine, Bharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for Covid-19 using an inactivated rabies vector platform.

Bharat Biotech is committed to global public health and will be involved in an end to end development of the vaccine including comprehensive clinical trials to achieve commercial licensure.”

Last month, Bharat Biotech partnered with FluGen and the University of Wisconsin–Madison (UWMadison) to develop and evaluate a Covid-19 vaccine candidate, CoroFlu.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology